Maria Gomes da Silva

Principal Investigator




Campus IPO
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE
Rua Prof. Lima Basto
1099-023 - Lisboa - Portugal

Phone: (+351) 217 229 800
Fax: (+351) 217 229 895
E-mail: mgsilva(at)ipolisboa.min-saude.pt

Main interests

1. Immune recovery and microenvironment

We are interested on studying interdependencies the immune system undertakes both in physiological status and disease. We aim to study lymphoid repertoire dynamics and lymphoid function in cancer at diagnosis and after treatment. Currently we are interested on studying biology of multiple myeloma and other B cell malignancies and its immunological responses to cancer and modulation by biological treatments.

2. Biology and treatment of lymphoid malignancies

We perform detailed phenotypic and genetic characterization of hematopoietic tumors, with an emphasis on refining diagnosis, prognosis, assessing treatment response and monitoring residual disease. We aim to study the biology and epidemiology of lymphomas; to define new diagnostic and prognostic factors in leukemia and lymphoma; and to translate our biological knowledge into clinical interventions through the participation in academic clinical trials at a local and european network level.

3. Epigenetic and transcriptional regulation in myeloid disorders

We study the transcriptional regulation of gene expression by epigenetic mechanisms: the role of epigenetic changes in pathogenesis and how these may be manipulated to treat diseases. Our current projects involve the elucidation of the roles of DNA methylation and histone acetylation in hereditary diseases, such as Inherited GPI Deficiency and Fanconi anemia, and in hematologic malignancies myelodysplasia, leukemia, and myeloproliferative neoplasms. Through pharmaceutical manipulation of epigenetic modifications in tissue specific housekeeping and disease genes we hope to generate a model for disease phenotype correction.


Research Projects

1.Immune recovery after Autologous Stem Cell Transplantation - modulation by Ig and potential clinical application
PI: Cristina João
Funding: Fundação para a Ciência e a Tecnologia (FCT) Project Grant, Portugal (PTDC/SAU-MII/65029/2006 e Associação Portuguesa contra a Leucemia (APCL 2006-30.4M.AP/MJ)

2.B cell modulation of T cells function and repertoire - immune characterization of lymphoma patients receiving chemotherapy with or without a B cell depleting agent, Rituximab
PI: Cristina João
Funding: Associação Portuguesa contra a Leucemia (APCL 2007)

3.Chronic Intermittent Eucapnic Hypoxia: systemic effects and evaluation of anti-hypertensive drugs efficacy (in collaboration with the PI: Maria Emília Monteiro, PhD, FCM, Universidade Nova de Lisboa)
Funding: Fundação para a Ciência e a Tecnologia (FCT) Project Grant, Portugal - PTDC/SAU-TOX/112264/2009

4.Flow cytometry for fast and sensitive diagnosis and follow up of hematological neoplasms (EUROFLOW)
PI: Paulo Lucio

5.European study group for minimal residual disease studies in leukemia and lymphoma (EURO MRD, EURO CLONALITY)
PI: Paula Gameiro

6.Regulation of ZAP70 and PTEN activity and stability in Chronica Lymphocytic leukemia: prognostic and therapeutic implications (collaboration with Instituto de Medicina Molecular, PI: João Barata)

7.Mechanisms of lymphoma resistanceto cytotoxic action of T gama-delta lymphocytes (collaboration with Instituto de Medicina Molecular, PI: Bruno Silva Santos)

8.Monocarboxylate transporters (MCTs) as putative therapeutic targets in acute Myeloid Leukemia (NRS/LPCC - "Terry Fox" Mar 2011, collaboration with PI: Jacinta Serpa)

9.Exploring the functional role of the mononuclear phagocyte system in diffuse large B cell lymphoma (Barts and London School of Medicine and Dentistry 2012 – collaboration with PI Prof. John Gribben).

10.Metaboloma do líquido cefalorraquidiano instrutivo para a formação de metastases no sistema nervoso central (FCT 2012, collaboration with PI Dra. Tânia Carvalho, PTDC/PIM-ONC/1242/2012)

11.Development of an autologous cellular immunotherapy for the treatment of leukemias: characterization and optimization T gama-delta lymphocytes for clinical use (FCT 2012, collaboration with PI Dr. Bruno Silva Santos, EXPL/BIM-ONC/O490/2012)

12.Tumor biology and microenvironment in chronic lymphocytic leukemia and its relationship with the progression of precursor lesions (FCT, collaboration with Dr. João Barata IMM)

13.Epidemiological, histological, clinical characterization and prognosis definition of primary extranodal and other indolent lymphomas (research projects in collaboration with the IELSG).

14.Epidemiology and registry of Hodgkin and non-Hodgkin lymphomas in Portugal and local patterns of lymphoma-related viral infections in Portugal (PI: Maria Gomes da Silva, in collaboration with UIC and ROR-Sul)

15.Epigenetic modifications in Fanconi Anemia: role in disease progression and effects of DNA hypomethylation and histone deacetylase inhibition”
Investigador Principal: António Almeida
Associação Portuguesa Contra a Leucemia 2011
NRS Liga Portuguesa Contra o Cancro – Terry Fox, 2013

17.Epigenetic modification in myeloproliferative neoplasms: molecular mechanisms and effects of histone deacetylase inhibition and DNA hypomethylation”
Investigador Principal: António Almeida
Fundação para a Ciência e Tecnologia 2012

18.Transcriptional regulation of the mannosyltransferase-encoding gene PIGM by GATA family transcription factors in Inherited Glycosylphosphatidylinositol Deficiency (IGD)”
Investigador Principal: António Almeida
Fundação para a Ciência e Tecnologia 2009

19.Transcriptional control of housekeeping genes by histone acetylation and SP1: molecular mechanisms and therapeutical potencial”.
Investigador Principal: António Almeida
Associação Portuguesa Contra a Leucemia 2009

Clinical Trials

In parallel with the translational research in the field of lymphoid and myeloid malignancies, we are involved in a variety of clinical trials testing different treatment options for multiple myeloma, lymphoma, chronic myeloid leukemia and myelodysplasia. These trials are sponsored by multiple european academic cooperative groups and the pharmaceutical industry. We are part of the steering committees and scientific advisory boards of some of the trials and actively participate in their design. We are also coordinating investigators in Portugal of some of the studies. The very close relationship between translational projects and clinical applications, as well as the international collaborations established, constitute a very enriching field of work for the hematology group.


Biology and treatment of lymphoid malignancies

  • Silva MG, Neto L, Guimarães A, Machado A, Parreira A, M Abecasis M. Long term follow-up of lymphocyte populations and cellular cytokine production in chronic GVHD patients treated with photophoresis. Haematologica/The Haematology J 2005, 90 (4): 564
  • Vieira L, Sousa AC, Matos P, Marques B, Alaiz H, Ribeiro MJ, Braga P, da Silva MG, Jordan P. Three-way translocation involves MLL, MLLT3 and a novel cell cycle control gene, FLJ10374, in the pathogenesis of acute myeloid leukemia with t(9;11,19) (p22; q23; p13.3). Genes Chromosomes and Cancer 2006, 45 (5): 455-469
  • Cristina Joao, Pedro Farinha, Maria Gomes da Silva, Carmo Martins, Mateus Crespo and José Cabeçadas. Cytogenetic abnormalities in MALT lymphomas and their precursor lesions from different organs. A fluorescence in situ hybridization (FISH) study. Histopathology 2007, 50 (2): 217-224
  • JHJM van Krieken, AW Langerak, EA Macintyre, M Kneba, JL Smith, R Garcia Sanz, GJ Morgan, A Parreira, TJ Molina, J Cabeçadas, P Gaulard, B Jasani, JF Garcia, M Ott, ML Hannsmann, F Berger, M Hummel, F Davi, M Brüggemann, FL Lavender, E Schuuring, PAS Evans, H White, G Salles, PJTA Groenen, P Gameiro, Ch Pott, JJM van Dongen. Improved reliability of lymphoma diagnostics via PCR-based clonality testing - Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 2007;27: 201-206.
  • PAS Evans, Ch Pott, PJTA Groenen, G Salles, F Davi, F Berger, JF Garcia, JHJM van Krieken, S Pals, Ph Kluin, E Schuuring, M. Spaargaren, E Boone, D González, B Martinez, R Villuendas, P Gameiro, TC Diss, K Mills, GJ Morgan, GI Carter, BJ Milner, D Pearson, M Hummel, W. Jung, M Ott, K Beldjord, C Bastard, MH Delfau-Larue, JJM van Dongen, TJ Molina, J Cabeçadas. Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets - Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 2007;27: 207-214.
  • Cátia Igreja, Margarida Courinha, Ana Sofia Cachaço, Teresa Pereira, José Cabeçadas, Maria Gomes da Silva, Sérgio Dias. Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitors in lymphoma patients. Hematológica/The Hematology J 2007 , 92: 469-477
  • Vieira L, Silva MGS: “The role of cell cycle control genes in the pathogenesis of human hematological neoplasms”. In “Cell Cycle control: new research” (Eds. Nathan H. Leroy e Noah T. Fournier). Nova Publishers, New York. 2008
  • Ana Elisabete Pires,Ana Filipa Afonso, Ana Queiro´s, M. Salome Cabral, Luis Porrata, Svetomir N. Markovic,y Srini V. Kaveri J, Maria Gomes da Silva, and Cristina João. Treatment With Polyclonal Immunoglobulin During T-cell Reconstitution Promotes Naïve T-cell Proliferation . J Immunotherapy 2010, 33: 618
  • Anita Q Gomes, Daniel V Correia, Ana R Grosso, Telma Lança, Cristina Ferreira, João F Lacerda, João T Barata, Maria Gomes da Silva and Bruno Silva-Santos. Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood  T cells. Haematologica 2010, 95 (8): 1397
  • Joana Perdigão, Helena Alaiz, Paulo Lúcio, M.D., Paula Gameiro, Marta Sebastião, Lara Neto, Maria Gomes da Silva, José Cabeçadas. Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia: Report of a rare disease association and review of the literature. J Hematopathology 2010, 3 (2): 91
  • Leila R. Martins, Paulo Lúcio, Milene C. Silva, Paula Gameiro, Maria G. Silva, João T. Barata. Targeting CK2 Overexpression and Hyperactivation as a Novel Therapeutic Tool in Chronic Lymphocytic Leukemia. Blood 2010, 116 (15): 2724
  • Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011 Jan 1;377(9759):42-51. Epub 2010 Dec 20.
  • Daniel V. Correia, Manuela Fogli, Kelly Hudspeth, Maria Gomes da Silva, Domenico Mavilio, and Bruno Silva-Santos. Differentiation of human peripheral blood Vδ1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 2011 Jul 28;118(4):992-1001. Epub 2011 Jun 1.
  • Perdigão J, Gomes da Silva M . Monosomal karyotype (MK) in myeloid malignancies. Atlas Genet Cytogenet Oncol Haematol. April 2011.
  • L Martins, P Lúcio, M Silva, P Gameiro, M Gomes da Silva, JT Barata. On CK2 regulation of chronic leukemia cell viability. Mol Cell Biochem. 2011 Oct;356(1-2):51-5. Epub 2011 Jul 13.
  • P Gameiro, M Sebastião, S. Spetalen, M Gomes da Silva, J Cabeçadas: The added value of immunoglobulin kappa light chain gene (IGK) rearrangement analysis in suspected B cell lymphomas: three illustrative cases. J Hematopathology 2012, 5:45
  • Carvalho A, Cunha C, Almeida AJ, Osório NS, Saraiva M, Teixeira-Coelho M, Pedreiro S, Torrado E, Domingues N, Gomes-Alves AG, Marques A, Lacerda JF, da Silva MG, Gomes M, Pinto AC, Torres F, Rendeiro P, Tavares P, Di Ianni M, Medeiros R, Heutink P, Bracci PM, Conde L, Ludovico P, Pedrosa J, Maciel P, Pitzurra L, Aversa F, Marques H, Paiva A, Skibola CF, Romani L, Castro AG, Rodrigues F. The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphoma. Genes Immun 2012 Feb;13(2):197-201. doi: 10.1038/gene.2011.59. Epub 2011 Aug 25
  • Vieira L, Vaz A, Matos P, Ambrósio AP, Nogueira M, Marques B, Jordan P, Gomes da Silva M. Three way translocation (X,20;16) (p11;q13;q23) in essential thrombocytemia implicates NFTAC2 in dysragulation of CSF2 expression and megakaryocyte proliferation. Genes Chromosomes and Cancer 2012; 51(12): 1093-108
  • Dekking EH, van der Velden VH, Varro R, Wai H, et al. Flow cytometric immunobead assay for fast and easy detection of PML-RARA fusion proteins for the diagnosis of acute promyelocytic leukemia. Leukemia. 2012 Sep;26(9):1976-85. doi: 10.1038/leu.2012.125. Epub 2012 May 8.
  • van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012 Sep;26(9):1908-75. doi: 10.1038/leu.2012.120. Epub 2012 May 3.
  • Tim C. Diss, Thierry J. Molina, Jose Cabeçadas, Anton W. Langerak. Molecular diagnostics in lymphoma: why, when and how to apply. Diagnostic Histopathology 2012, 18, 2 ,53-63.
  • J Han van Krieken, Jose Cabeçadas, Patricia J. T. A Groenen Clonality testing. Teamwork by pathologist and molecular biologist. An introduction to the clonality issue of the journal of haematopathology.. J Hematopathol 2012 5: 3-5 DOI 10.1007/s12308-12-0143y.
  • Falko Fend, José Cabecadas, Philippe Gaulard, Elaine S. Jaffe, Philip Kluin, Isinsu Kuzu, LoAnn Peterson, Andrew Wotherspoon, Christer Sundström. Early lesions in lymphoid neoplasia. Journal of Hematopathology. September 2012, Volume 5, Issue 3, pp 169-199
  • AW Langerak, PJTA Groenen, M Bruggemann, K Beldjord, C Bellan, L Bonello, E Boone, GI Carter, M Catherwood, F Davi, M-H Delfau-Larue, T Diss, PAS Evans, P Gameiro, R Garcia Sanz, D Gonzalez, D Grand, Å Hakansson, M Hummel, H Liu, L Lombardia, EA Macintyre, BJ Milner, S Montes-Moreno, E Schuuring, M Spaargaren, E Hodges and JJM van Dongen. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 2012, 26: 2159-71; doi: 10.1038/leu.2012.246.
  • C Meyer, J Hofmann, T Burmeister, D Groger, TS Park, M Emerenciano, M Pombo de Oliveira, A Renneville, P Villarese, E Macintyre, H Cave´ , E Clappier, K Mass-Malo, J Zuna, J Trka, E De Braekeleer, M De Braekeleer, SH Oh, G Tsaur, L Fechina, VHJ van der Velden, JJM van Dongen, E Delabesse, R Binato, MLM Silva, A Kustanovich, O Aleinikova, MH Harris, T Lund-Aho, V Juvonen, O Heidenreich, J Vormoor, WWL Choi, M Jarosova, A Kolenova, C Bueno, P Menendez, S Wehner, C Eckert, P Talmant, S Tondeur, E Lippert, E Launay, C Henry, P Ballerini, H Lapillone, MB Callanan, JM Cayuela, C Herbaux, G Cazzaniga, PM Kakadiya, S Bohlander, M Ahlmann, JR Choi, P Gameiro, DS Lee, J Krauter, P Cornillet-Lefebvre, G Te Kronnie, BW Schafer, S Kubetzko, CN Alonso, U zur Stadt, R Sutton, NC Venn, S Izraeli, L Trakhtenbrot, HO Madsen, P Archer, J Hancock, N Cerveira, MR Teixeira, L Lo Nigro, A Moricke, M Stanulla, M Schrappe, L Sedek, T Szczepanski, CM Zwaan, EA Coenen, MM van den Heuvel-Eibrink, S Strehl, M Dworzak, R Panzer-Grumayer, T Dingermann, T Klingebiel and R Marschalek. The MLL recombinome of acute leukemias in 2013. Leukemia 2013, 27:1-12. doi:10.1038/leu.2013.135.
  • H. Tilly, U. Vitolo, J. Walewski, M. Gomes da Silva, O. Shpilberg, M. André, M. Pfreundschuh, M. Dreyling and on behalf of the ESMO Guidelines Working Group: Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol (2012) 23 (suppl 7): vii78-vii82
  • AB Afonso, LN Justo, AC Queirós, C Fesel, MS Cabral, M Gomes da Silva, L Porrata, S Markovic, AE Pires, C João: Treatment with low doses of polyclonal immunoglobulin improves B cell function during immune reconstitution in a murine model: J Clin Immunol 2013 Feb, 33(2)407-419
  • Filipa Moita, Isabel Bogalho, Helena Alaiz, Joana Parreira, Maria Jesus Frade, Albertina Nunes, Maria Gomes da Silva. Clonal Hypereosinophilia with ETV6 Rearrangement Evolving to T-Cell Lymphoblastic Lymphoma: A Case Report and Review of the Literature. Case Reports in Hematology, vol. 2013, Article ID 652745, 4 pages, 2013. doi:10.1155/2013/652745.
  • Diamond J, Gomes da Silva M. Mechanisms of Resistance to BCR-ABL Kinase Inhibitors. Acta Med Port. 2013 Jul-Aug;26(4):402-408. Epub 2013 Aug 30.
  • Leila R. Martins, Paulo Lúcio, Alice Melão, Bruno A. Cardoso, Ryan Stansfield, Maria Teresa Sabrina Bertilaccio, Paolo Ghia, Denis Drygin, Maria G. Silva, João T. Barata. Targeting chronic lymphocytic leukemia using CX-4945, a clinical-stage CK2-specific small molecule inhibitor. Leukemia 2013 (accepted for publication)
  • Rita Coutinho1, Andrew James Clear1, Andrew Owen1,2, Andrew Wilson1, Janet Matthews1, Abigail Lee1,2, Rute Alvarez3, Maria Gomes da Silva3, José Cabeçadas4, Maria Calaminici1,2 and John G. Gribben. Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for Diffuse Large B-cell Lymphoma: implications for therapeutic strategies. Clinical Cancer Research 2013 (accepted for publication)
  • Ayoma D. Attygalle, José Cabeçadas, Philippe Gaulard, Elaine S. Jaffe, Daphne de Jong, Young Hyeh Ko, Jonathan Said and Wolfram Klapper . Peripheral T- and NK-cell lymphomas and their mimics; taking a step forward – Report on the Lymphoma Workshop of the XVI meeting of the European Association for Haematopathology and the Society for Hematopathology in Lisbon 2012 Histopathology Accepted manuscript online: 13 AUG 2013, DOI: 10.1111/his.12251 (in press)

Immune recovery and microenvironment

  • Costa N, Pires AE, Gabriel AM, Goulart LF, Pereira C, Leal B, Queiros AC, Chaara W, Moraes-Fontes MF, Vasconcelos C, Ferreira C, Martins J, Bastos M, Santos MJ, Pereira MA, Martins B, Lima M, João C, Six A, Demengeot J, Fesel C. Broadened T-cell Repertoire Diversity in ivIg-treated SLE Patients is also Related to the Individual Status of Regulatory T-cells. J Clin Immunol. 2013 Feb;33(2):349-60.
  • Ana B Afonso, Lígia N Justo, Ana C Queirós, Constantin Fesel,Maria S Cabral, Maria G da Silva, Luis Porrata, Svetomir Markovic, Ana E Pires, Cristina João. Treatment with low doses of polyclonal immunoglobulin improves B cell function during immune reconstitution. J Clin Immunol. 2013 Feb;33(2):407-19
  • João C, Figueiredo A, Martins HF. Advantageous use of lenalidomide in multiple myeloma: discussion of three case studies. Curr Opin Oncol.;24 Suppl 2:S13-20, 2012. (http://www.ncbi.nlm.nih.gov/pubmed/22245805)
  • Pires AE, Barahona AF; Queirós A; Cabral MS, Porrata L; Markovic SN; Gomes MS, Kaveri SV, João C. Treatment with polyclonal Immunoglobulin during T-cell reconstitution promotes naïve T cell proliferation. Journal of Immunotherapy, 33: 618-625, 2010.
  • João C., Farinha P., Gomes da Silva M., Martins C., Crespo M., Cabeçadas J. MALT1 gene rearrangement is uncommon in primary breast MALT lymphomas. Histopathology, 50:217-224, 2007.
  • Cristina João. Immunoglobulin is a highly diverse self molecule that improves cellular diversity and function during immune reconstitution Medical Hypotheses, 68:158-161, 2007.
  • Cristina João, Brenda M. Ogle, Susan Geyer. Immunoglobulin promotes the diversity and the function of T cells. European Journal of Immunology, 36:1718-1728, 2006.
  • Cristina João, Luis F. Porrata, David J. Inwards, Stephen Ansell, Ivana Micallef, Patrick Johnston, Dennis A. Gastineau, Svetomir N. Markovic. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in Mantle Cell Lymphoma. Bone Marrow Transplantation, 37:865-871, 2006.
  • João C., Ogle B., Gay-Rabinstein C., Platt J. L., Cascalho M. B cell-dependent TCR diversification. Journal of Immunology, 172:4709-4716, 2004.
  • Ogle B., Cascalho M., João C., Taylor W., West J. L., Platt L. J. Direct measurement of lymphocyte receptor diversity. Nucleic Acids Research, 31:e139, 2003.
  • João, C., Carrilho C., Leite A., Miranda C., Serra I., Revês L., Brandão T., Freitas P. Advantageous use of thorax x-ray for the localization of pneumothoraces in ventilated patients. Revista Portuguesa Medicina Intensiva 2:201-02, 2001. (ftp://ftp.spci.org/revista/Portugues/rev102/pneumotorax.pdf)
  • João, C., Matias T., Sá J. Paget’s disease associated with myelofibrosis and myeloid metaplasia – a common pathophysiology?. Haematologica 86:E22, 2001. (http://www.haematologica.org/e-letters/past/2001_22.html)
  • Davis SJM, Svensson E, Albarella U, Detry C,Götherström A, Pires AE, Ginja C. Molecular and Osteometric Sexing Of Cattle Metacarpals: A Case Study From 15th Century AD Beja, Portugal. Journal of Archaeological Science; 2012 39(5): 1445–1454
  • Pires A.E. & Ginja C. Why look back? Methods and relevance of ancient DNA studies. Cadernos do GEEvH 2013 ;2 (1): 7-23

Epigenetic and transcriptional regulation in myeloid disorders

  • Belo H, Silva G, Cardoso BA, Porto B, Minguillon J, Barbot J, Coutinho J, Casado JA, Benedito M, Saturnino H, Costa E, Bueren JA, Surralles J, Almeida A. Epigenetic Alterations in Fanconi Anaemia: Role in Pathophysiology and Therapeutic Potential. PLoS One. 2015 Oct 14;10(10):e0139740. doi: 10.1371/journal.pone.0139740. eCollection 2015.
  • Silva G., Cardoso B.A., Belo H., and Almeida M.A. Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms. PLoS ONE 8(1): e53766. doi:10.1371/journal.pone.0053766 – Impact Factor 4,092
  • Francesca Pierdomenico; Antonio Almeida. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: effective management with concomitant prednisolone. Leukemia Research. 2012 Aug;36(8):1071-3. Epub May 21– Impact Factor2,923
  • Michael Thorpe; Ana Montalvão; Filipa Moita; FrancescaPierdomenico; Antonio Almeida. Treatment of chronic myelomonocytic leukaemia with 5-azacitidine: a case series and literature review.Leukemia Research, Epub May 2012– Impact Factor 2,923
  • Nolte F, Angelucci E, Beris P, Macwhannell A, Selleslag D, Schumann C, Xicoy B, Almeida A, Guerci-Bresler A, Sliwa T, Muus P, Porter J, Hofmann WK. Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox. Leuk Res. 2011 Sep;35(9):1131-5.– Impact Factor 2,923
  • Almeida A, Castro I, Coutinho J, Guerra L, Marques H, Pereira AM. Recommendations for diagnosis, treatment and monitoring of chronic myeloid leukemia. Acta Med Port. 2009 Sep-Oct;22(5):537-44. Epub 2009 Oct 22.– Impact Factor 0,091
  • Almeida A, Layton M, Karadimitris A. Inherited GPI Deficiency. Chapter 16, The Enzymes, Vol. XXVI, 2009
  • Almeida A, Layton M, Karadimitris A. Inherited glycosylphosphatidyl inositol deficiency: A treatable CDG. Biochim Biophys Acta. 2009 Sep;1792(9):874-80. Epub 2009 Jan 9.– Impact Factor 2,958
  • Almeida AM, Layton, DM. Sickle Cell Disease in Conn’s Current Therapy 2008. Elsevier, USA.
  • A.Almeida AM, Murakami Y, Baker A, Maeda Y, Roberts IA, Kinoshita T, Layton DM, Karadimitris A. Targeted therapy for inherited GPI deficiency. New England Journal of Medicine. 2007; 356(16):1641-7.– Impact Factor 52,59
  • Almeida AM, Murakami Y, Layton DM, Hillmen P, Sellick GS, Maeda Y, Richards S, Patterson S, Kotsianidis I, Mollica L, Crawford DH, Baker A, Ferguson M, Roberts I, Houlston R, Kinoshita T, Karadimitris A. Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency. Nature Medicine.(2006), 12(7), pp 846-51.– Impact Factor 28,588
  • Kotsianidis I, Silk JD, Spanoudakis E, Patterson S, Almeida A, Schmidt RR, Tsatalas C, Bourikas G, Cerundolo V, Roberts IA, Karadimitris A. Regulation of hematopoiesis in vitro and in vivo by invariant NKT cells. Blood.(2006) 107(8), pp 3138-44.– Impact Factor 10,370
  • Patterson S, Kotsianidis I, Almeida A, Politou M, Rahemtulla A, Matthew B, Schmidt RR, Cerundolo V, Roberts IA, Karadimitris A. Human invariant NKT cells are required for effective in vitro alloresponses. Journal of Immunology, (2005), 175, pp5087-94– Impact Factor 6,387
  • Almeida A, Roberts I. Bone involvement in Sickle Cell Disease. British Journal of Haematology, (2005), 129, pp.482-90.– Impact Factor 4,08
  • Daniel Y, Witchlow B, Almeida A. Automated computer result reporting for haemoglobinopathy screening. Clinical and Laboratory Haematology, (2004), 26, pp. 21-4.– Impact Factor 0,869
  • Henthorn JS, Almeida AM, Davies SC. Neonatal Screening for Sickle Cell Disorders. British Journal of Haematology. (2004), 124, pp. 259-63.– Impact Factor 3,195
  • Hunt BJ, Gattens M, Khamashta M, Nelson-Piercy C, Almeida A. Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event. Blood Coagulation and Fibrinolysis. (2003), 14, pp. 735-9.– Impact Factor 1,319
  • Amrolia, P, Almeida, AM, Davies, SC, Roberts, I. Therapeutic challenges in sickle cell disease Part 2: a problem-orientated approach. British Journal of Haematology (2003) 120, pp. 737-43. –Impact Factor 3,267
  • Almeida, AM, Khair, K, Hann, I, Liesner, R. The use of recombinant factor VIIa in children with inherited platelet function disorders. British Journal of Haematology (2003), 121, pp. 477-81. –Impact Factor 3,267
  • Almeida, A, Khair, K, Hann, I, Liesner, R. Unusual presentation of Factor XIII deficiency. Haemophilia (2002), 8, pp. 703-705.–Impact Factor 1,113
  • Short Report: Fludarabine-based stem cell transplantation protocol for Fanconi's anaemia in myelodysplastic transformation. McCloy, M, Almeida, A, Daly, P, Vulliamy, T, Roberts, I, Dokal, I. British Journal of Haematology (2001), 112, pp. 427-429.–Impact Factor 2,815
  • Almeida, AM, Henthorn, J, Davies, SC. Neonatal Screening for Haemoglobinopathies: the results of a ten year programme in an English health region. British Journal of Haematology (2001), 112, pp. 32-35. – Impact Factor 2,815


Anastasios Karadimitris PhD, MRCP, FRCPath
Professor of Haematology and Consultant Haematologist
Department of Haematology, Imperial College Healthcare NHS Trust
Hammersmith Hospital
London, UK

Prof. Juan Bueren, MD, PhD and Jose Casado, PhD
Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), DepartmentofHematopoiesisand Gene Therapy
Madrid, Spain

Prof. José Barbot, Jorge Coutinho, Esmeralda Cleto and Emília Costa, MD
Centro Hospitalar do Porto, Hospital Maria Pia/ Hospital Santo António
Departmento Haematology ,
Porto, Portugal

Prof. Orquídea Freitas, MD.
Centro Hospitalar Lisboa Central EPE, Hospital da Estefânia,
Lisboa, Portugal

Prof. Manuela Benedito, Letícia Ribeiro and Herma Saturnino, MD
Centro Hospitalar de Coimbra, Hospital Pediátrico de Coimbra/ Hospital dos Covões, DepartmentofPediatricandHaematology,
Coimbra, Portugal

Prof.Beatriz Porto, PhD
Institute for theBiomedicalSciences Abel Salazar – ICBAS,
Porto, Portugal

Prof. Paula Ambrósio and José Furtado,
National Health Institute Doutor Ricardo Jorge –INSA,
Department of Cytogenetic,
Lisboa, Portugal

ESLO (European Scientific Foundation of Hemato-Oncology Laboratories)

EUTOS (European Treatment and Outcome Study in CML)

Lymphoma Study Association (LYSA)

International Extranodal Lymphoma Study Group (IELSG)

European Mantle Cell Network (EMCN)

Fundazione Italiana di Linfomi (FIL)

Instituto de Medicina Molecular (IMM)

Luis Porrata (http://www.mayoclinic.org/bio/11732784.html) Svetomir Markovic (http://mayoresearch.mayo.edu/mayo/research/staff/markovic_sn.cfm) Mayo Clinic, USA Adrien Six (http://www.i3-immuno.fr/) Hôpital Pitié-Salpétrière, France Salomé Cabral (http://www.ceaul.fc.ul.pt/mbr.html?lang=english&membro=salome@fc.ul.pt) FCUL, Portugal Constantin Fesel, PhD
IGC, Portugal
Maria Emília Monteiro, PhD
Anastasios Karadimitris PhD, MRCP, FRCPath
Professor of Haematology and Consultant Haematologist
Department of Haematology, Imperial College Healthcare NHS Trust
Hammersmith Hospital
London, UK

Team photos